Aripiprazole alone or in combination for acute mania

Cochrane Database of Systematic Reviews

Volumn 2013, Issue 12, 2013, Pages

  Brown, Rachel ^a   Taylor, Matthew J ^b   Geddes, John ^c  

^a OXFORD HEALTH NHS FOUNDATION TRUST   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c WARNEFORD HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; CHOLINERGIC RECEPTOR BLOCKING AGENT; HALOPERIDOL; LITHIUM; LORAZEPAM; PLACEBO; PROLACTIN; VALPROIC ACID; LITHIUM DERIVATIVE; NEUROLEPTIC AGENT; PIPERAZINE DERIVATIVE; QUINOLONE DERIVATIVE; TRANQUILIZER;

ABNORMAL INVOLUNTARY MOVEMENT SCALE; ADD ON THERAPY; AKATHISIA; ANXIETY; BARNES AKATHISIA SCALE; BIPOLAR DISORDER; BODY WEIGHT GAIN; CLINICAL GLOBAL IMPRESSION SCALE; CONSTIPATION; DEPRESSION; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; EXTRAPYRAMIDAL SYMPTOM; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; HYPERTENSION; INSOMNIA; LIMB PAIN; MANIA; MONOTHERAPY; MONTGOMERY ASBERG DEPRESSION RATING SCALE; MOTOR DYSFUNCTION; NAUSEA; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; PSYCHOSIS; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; REVIEW; SIDE EFFECT; SIMPSON-ANGUS SCALE; SOMNOLENCE; SYSTEMATIC REVIEW; TREMOR; YOUNG MANIA RATING SCALE; ADOLESCENT; ADULT; CHILD; DRUG COMBINATION; DYSKINESIA; META ANALYSIS; METHODOLOGY;

ADOLESCENT; ADULT; ANTIMANIC AGENTS; ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; CHILD; DRUG THERAPY, COMBINATION; DYSKINESIA, DRUG-INDUCED; HALOPERIDOL; HUMANS; LITHIUM COMPOUNDS; PIPERAZINES; QUINOLONES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; VALPROIC ACID;

EID: 84897574396     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD005000.pub2     Document Type: Review

References (92)

1. Bristol-Myers Squibb. Clinical study report synopsis, protocol CN138-007 [data on file].
2. El Mallakh RS, Vieta E, Rollin L, Marcus R, Carson WH, McQuade R. A comparison of two fixed doses of aripiprazole with placebo in acutely relapsed, hospitalized patients with bipolar disorder I (manic or mixed) in subpopulations (CN138-007). European Neuropsychopharmacology 2010;11:776-83.
3. Findling RL, Nyilas M, Forbes RA, McQuade RD, Jin N, Iwamoto T, et al.Acute treatment of pediatric bipolar I disorder, Manic or mixed episode, with aripiprazole:randomized, double-blind, placebo-controlled study [NCT00110461]. Journal of Clinical Psychiatry 2009;70(10):1441-51.
4. Findling RL, Youngstrom EA, Zhao J, Marcus R, Andersson C, McQuade R, et al.Respondent and item level patterns of response of aripiprazole in the acute treatment of pediatric bipolar i disorder. Journal of Affective Disorders 2012;143(1-3):231-5.
5. Loze J-Y, Forbes RA, Zhao J, Chen C-F, Carson W, Iwamoto T, et al.Line item analysis in child and adolescent patients with bipolar I disorder treated with Aripiprazole in an acute study (31-03-240) [conference abstract]. European Child and Adolescent Psychiatry [abstracts from the 14th International Congress of ESCAP European Society for Child and Adolescent Psychiatry] 2011;20:185.
6. Loze J-Y, Mankoski R, Zhao J, Carson W, Youngstrom E, Findling R, et al.Line item analysis in paediatric patients with bipolar I disorder treated with aripiprazole [conference abstract]. European Psychiatry [abstracts from the 19th European Congress of Psychiatry, EPA 2011 Mar 12-15; Vienna, Austria] 2011:26.
7. Mankoski R, Zhao J, Carson WH, Mathew SJ, Forbes RA. Young mania rating scale line item analysis in pediatric subjects with bipolar i disorder treated with aripiprazole in a short-term, double-blind, randomized study. Journal of Child and Adolescent Psychopharmacology 2011;21(4):359-64.
8. Mankoski R, Zhao J, Carson WH, Nyilas M, Mathew S, Forbes RA. YMRS line item analysis in pediatric patients with bipolar i disorder treated with aripiprazole [conference abstract]. 163rd Annual Meeting of the American Psychiatric Association; 2010 May 22-26; New Orleans, LA 2010:NR4-70.
9. Youngstrom E, Zhao J, Mankoski R, Forbes RA, Marcus RM, Carson W, McQuade R, et al.Clinical significance of treatment effects with aripiprazole versus placebo in a study of manic or mixed episodes associated with pediatric bipolar I disorder. Journal of Child and Adolescent Psychopharmacology 2013;23(2):72-9.
10. Jody D, Marcus R, Keck P, Saha AR, Iwamoto T, Tourkodimitris S, et al.Aripiprazole vs placebo in acute mania [abstract]. International Journal of Neuropsychopharmacology [Proceedings of the 23rd Congress of the Collegium Internationale Neuro-Psychopharmacologicum; 2002 June 23-27; Montreal, Canada] 2002;5(Suppl 1):57.
11. Keck PE, Marcus R, Tourkodimitris S, Ali M, Liebeskind A, Saha A, et al.A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania. American Journal of Psychiatry 2003;160(9):1651-8.
12. Marcus R, Saha A, Jody D, Tourkodimitris S, Archibald D, Iwamoto T. Aripiprazole versus placebo in acute mania. New Research Abstracts, 155th Annual Meeting of the American Psychiatric Association; 2002 May 18-23; Philadelphia, Pennsylvania, USA. San Francisco: American Psychiatric Association, 2002:p86, Abstract no: NR314.
13. Marcus R, Saha A, Jody D, Tourkodimitris S, Archibald D, Iwamoto T. Aripiprazole versus placebo in acute mania [abstract]. European Neuropsychopharmacology [Proceedings of the 15th International Congress of the European College of Neuropsychopharmacology; 2002 October 5-9; Barcelona, Spain] 2002;12(Suppl 3):S289.
14. Bristol Myers-Squibb. Addendum to Clinical Study Report for Study CN138135: A multicenter, randomized, double-blind, placebo-controlled study of aripiprazole monotherapy in the treatment of acutely manic patients with bipolar I disorder. Clinical Trials Results Bristol-Myers Squibb [http://ctr.bms.com] 2008.
15. Bristol Myers-Squibb. Clinical study report synopsis: A multicenter, randomized, double-blind, placebo-controlled study of aripiprazole monotherapy in the treatment of acutely manic patients with bipolar I disorder [CN138135]. Clinical Trials Results Bristol-Myers Squibb [http://ctr.bms.com] 2008.
16. El-Mallakh RS, Marcus R, Baudelet C, McQuade R, Carson WH, Owen R. A 40-week double-blind aripiprazole versus lithium follow-up of a 12-week acute phase study (total 52 weeks) in bipolar i disorder. Journal of Affective Disorders 2012;136(3):258-66.
17. Keck PE, Orsulak PJ, Cutler AJ, Sanchez R, Torbeyns A, Marcus RN, et al.Aripiprazole monotherapy in the treatment of acute bipolar I mania: a randomised, double-blind, placebo and lithium controlled study. Journal of Affective Disorders 2009;112:36-49.
18. Bristol Myers Squibb. Study to evaluate the efficacy and safety of aripiprazole administered with lithium or valproate over 12 weeks in the treatment of mania in bipolar I disorder. http://clinicaltrials.gov/show/NCT00665366 2013.
19. Bristol-Myers Squibb. Clinical study report synopsis: a multicenter, randomized, double-blind study of aripiprazole versus placebo in the treatment of acutely manic patients with bipolar disorder [CN138074]. Clinical Trials Results Bristol-Myers Squibb [http://ctr.bms.com] 2003.
20. Hadjakis WJMarcus R, Abou-Gharbia N, Tourkodimitris S, Archibald DG, Carson WH, Iwamoto T, et al.Aripiprazole in acute mania: results from a second placebo-controlled study. Bipolar Disorders 2004;6(Suppl 1):39-40.
21. Sachs G, Sanchez R, Marcus R, Stock E, McQuade R, Carson W, et al.Aripiprazole in the treatment of acute manic or mixed episodes in patients with bipolar I disorder: a 3 week placebo-controlled study. Journal of Psychopharmacology 2006;20(4):536-46.
22. Sachs GS, Sanchez R, Marcus RN, Kujawa MJ, Archibald DG, Carson WH Jr, et al.Aripiprazole versus placebo in patients with an acute manic or mixed episode. New Research Abstracts, 157th Annual Meeting of the American Psychiatric Association; 2004 May 1-6; New York, NY. 2004:p279, Abstract No:NR742.
23. Tramontina S, Zeni CP, Ketzer CR, Phuela GF, Narvaez J, Rohde LA. Aripiprazole in children and adolescents with bipolar disorder comorbid with attention-deficit/hyperactivity disorder:a pilot randomised clinical trial [NCT00116259]. Journal of Clinical Psychiatry 2009;70(5):756-64.
24. Bourin M, Auby P, Marcus RN, Swanik R, McQuade RD, Iwamoto T, et al.Aripiprazole versus haloperidol for maintained treatment effect in acute mania. New Research Abstracts 156th Annual Meeting of the American Psychiatric Association; 2003 May 17-22; San Francisco CA. 2003:p175, Abstract No:NR467.
25. Bourin M, Auby P, Swanik E, Marcus R, McQuade R, Iwamoto T, et al.Aripiprazole vs. haloperidol for maintained treatment effect in acute mania. European Neuropsychopharmacology [abstracts of the 16th Congress of the European College of Neuropsychopharmacology; 2003 September 20-24; Prague, Czech Republic] 2003;13(Suppl 4):S333.
26. Bristol Myers-Squibb. Clinical study report synopsis: a multicenter, randomized, double-blind study of aripiprazole and haloperidol in the maintained response to treatment for an acute manic episode (Protocol CN138008). Clinical Trials Results Bristol-Myers Squibb [http://ctr.bms.com] 2003.
27. Bristol-Myers Squibb. Cumulative 26-Week Clinical Study Report Including the 14-Week Extension Phase CN138008: a multicenter, randomized, double-blind study of aripiprazole and haloperidol in the maintained response to treatment for an acute manic episode. Clinical Trials Results Bristol-Myers Squibb [http://ctr.bms.com] 2003.
28. Sanchez R, Bourin M, Auby P, Swanik R, Marcus R, McQuade RD, et al.Aripiprazole vs. haloperidol for maintained treatment effect in acute mania. Bipolar Disorders [Posters - Fifth International Conference on Bipolar Disorder; 2003 June 12-14; Pittsburgh, PA, USA] 2003;5(Suppl1):p80, Abstract no:174.
29. Vieta E, Bourin M, Sanchez R, Marcus R, Stock E, McQuade R, et al.Effectiveness of aripiprazole v. haloperidol in acute bipolar mania: double-blind, randomised, comparative 12-week trial. British Journal of Psychiatry 2005;187:235-42.
30. Bristol-Myers Squibb. Addendum 01 to Clinical Study Report for Study CN138134: efficacy of aripiprazole in combination with valproate or lithium in the treatment of mania in patients with bipolar I disorder partially nonresponsive to valproate or lithium monotherapy. Clinical Trials Results Bristol-Myers Squibb [http://ctr.bms.com] 2008.
31. Bristol-Myers Squibb. Clinical study synopsis report: efficacy of aripiprazole in combination with valproate or lithium in the treatment of mania in patients with bipolar I disorder partially nonresponsive to valproate or lithium monotherapy [CN138134]. Clinical Trials Results Bristol-Myers Squibb [http://ctr.bms.com] 2007.
32. Vieta E, T'joen C, MacQuade RD, Carson WHJr, Marcus RN, Sanchez R, et al.Efficacy of adjunctive aripiprazole to either valproate or lithium in bipolar mania patients partially nonresponsive to valproate or lithium monotherapy: a placebo-controlled study [NCT00257972, CN138-134] [Comment in Am J Psychiatry. 2008 Oct;165(10):1234-6]. American Journal of Psychiatry 2008;165(10):1316-25.
33. Bristol-Myers Squibb. Clinical study synopsis report: a multicenter, randomized, double-blind, placebo-controlled study of aripiprazole monotherapy in the treatment of acutely manic patients with bipolar I disorder [CN138162]. Clinical Trials Results Bristol-Myers Squibb [http://ctr.bms.com] 2007.
34. Young AH, Oren DA, Lowy A, McQuade RD, Marcus RN, Carson WH, et al.Aripiprazole monotherapy in acute mania: 12 week randomised placebo- and haloperidol-controlled study [NCT00097266, CN138-162]. British Journal of Psychiatry 2009;194(1):40-8.
35. Bristol Myers Squibb. Synpotic Clinical Study Report: a multicentre, randomized, double-blind, placebo-controlled study of aripiprazole in the treatment of acutely manic patients with bipolar disorder [CN138077]. Clinical Trials Results Bristol Myers Squibb [http://ctr.bms.com].
36. Abbar M, Khan A, Rollin L, Sanchez R, Carson W, Morris B, et al.Efficacy of adjunctive aripiprazole to lithium or valproate in the long-term treatment of mania in subjects with bipolar I disorder (CN138-189) [conference abstract]. European Psychiatry [abstracts from the 19th European Congress of Psychiatry, EPA 2011 Mar 12-15; Vienna, Austria] 2011;26(Suppl 1):186. [DOI: ]
37. Ammerman D, Fyans P, Marler SV, Forbes RA, Rahman Z, Baker RA, et al.Aripiprazole with lithium or valproate in the long-term treatment of mania in patients with bipolar I disorder (CN138-189) [conference poster P3]. Bipolar Disorders [abstracts of the 9th International Conference on Bipolar Disorder; 9 - 11 June 2011, Pittsburgh, PA United States] 2011;13(s1):27.
38. Bristol Myers Squibb. Clinical study report synopsis: efficacy of aripiprazole in combination with lithium or valproate in the long term treatment of mania in patients with bipolar I disorder partially nonresponsive to lithium or valproate monotherapy [CN138189]. Clinical Trials Results Bristol Myers Squibb [http://ctr.bms.com].
39. De Hert M, Kemp DE, Fyans P, Rahman Z, Marler SV, Eudicone JM, et al.Long-term metabolic effects of aripiprazole adjunctive to lithium, valproate or lamotrigine [conference abstract]. European Neuropsychopharmacology [abstracts from the 24th Congress of the European College of Neuropsychopharmacology, ECNP 2011 Paris France, 3-7 Sept] 2011;21(Suppl 3):S431.
40. Fountoulakis KN, Ammerman D, Fyans P, Marler SV, Forbes RA, Rahman Z, et al.Effect of aripiprazole adjunctive to lithium or valproate on manic and mixed subpopulations: 52-week, double-blind, randomised relapse prevention trial [conference abstract]. European Neuropsychopharmacology [abstracts from the 24th Congress of the European College of Neuropsychopharmacology, ECNP 2011 Paris France, 3-7 Sept] 2011;21(Suppl 3):S429.
41. Marcus R, Khan A, Rollin L, Morris B, Timko K, Carson W, et al.Efficacy of aripiprazole adjunctive to lithium or valproate in the long-term treatment of patients with bipolar I disorder with an inadequate response to lithium or valproate monotherapy: a multicenter, double-blind, randomized study [CN138-189]. Bipolar Disorders 2011;13(2):133-44.
42. Masand PS, Tohen M, Everitt AL, Baker RA, Forbes RA, Carlson BX. Does shorter vs. longer time to stabilization in patients with bipolar i disorder predict relapse prevention? (CN138-189) [conference poster P132]. Bipolar Disorders [abstracts of the 9th International Conference on Bipolar Disorder; 9 - 11 June 2011, Pittsburgh, PA United States] 2011;13(s1):70.
43. Owen R, Rollin L, Khan A, Sanchez R, Carson W, Morris B, et al.Efficacy of adjunctive aripiprazole to lithium or valproate in the long-term treatment of mania in subjects with bipolar i disorder (CN138-189) [conference abstract]. 163rd Annual Meeting of the American Psychiatric Association; 2010 May 22-26; New Orleans, LA 2010:NR4-69.
44. Yatham LN, Fountoulakis KN, Rahman Z, Ammerman D, Fyans P, Marler SV, et al.Efficacy of aripiprazole versus placebo as adjuncts to lithium or valproate in relapse prevention of manic or mixed episodes in bipolar i patients stratified by index manic or mixed episode. Journal of Affective Disorders 2013;147(1-3):365-72.
45. Korea Otsuka International Asia Arab. A double-blind, randomized, placebo-controlled trial of aripiprazole plus valproate in the short-term and long-term treatment of bipolar disorder. http://clinicaltrials.gov/show/NCT00484471 2012.
46. OtsukaPharmaceutical Co, Ltd . A multicentre investigative study of the safety and efficacy of long-term administration of aripiprazole in combination with mood stabilizer for the treatment of patients with bipolar disorder experiencing a manic or mixed episode. http://clinicaltrials.gov/ct2/show/NCT00606229 2011.
47. Otsuka Pharmaceutical Development & Commercialization, Inc . Efficacy, safety, and tolerability of an intramuscular formulation of aripiprazole (OPC-14597) as maintenance treatment in bipolar I patients. http://clinicaltrials.gov/ct2/show/NCT01567527 (accessed 19 August 2013).
48. Bhak WM, Woo YS, Chung MY, Kim DH, Yoon BH, Lee JH, et al.A randomised, double-blind, placebo-controlled 24 week trial of aripiprazole in recently remitted bipolar I patients [conference abstract, NCT00545675]. Neuropsychopharmacology [abstracts from the 24th Congress of the European College of Neuropsychopharmacology, ECNP 2011 Paris France, 3-7 Sept] 2011;21(Suppl 3):S482.
49. Korea Otsuka Pharmaceutical Co, Ltd . Multicentre, double-blind, randomized, comparative phase 4 clinical trial to evaluate the efficacy and safety of co-administration of Abilify and Depakote in 24 week treatment of mania in patients with bipolar disorder remitted after 6-week treatment with Abilify and Depakote. http://clinicaltrials.gov/ct2/show/NCT00545675 2010.
50. Woo YS, Bahk WM, Chung MY, Kim DH, Yoon BH, Lee JH, et al.Aripiprazole plus divalproex for recently manic or mixed patients with bipolar I disorder: a 6 month, randomized, placebo-controlled, double-blind maintenance trial. Human Psychopharmacology 2011;26(8):543-53. [DOI: ]
51. Zeni CP, Tramontina S, Ruffoni K, Pheula GF, Rohde LA. Methylphenidate combined with aripiprazole in children and adolescents with bipolar disorder and attention-deficit/hyperactivity disorder: a randomised crossover trial. Journal of Child and Adolescent Psychopharmacology 2009;19(5):553-61.
52. Bristol Myers Squibb. Clinical study report synopsis: a randomised, double-blind comparison of the efficacy and safety of aripiprazole intramuscular formula, lorazepam, or placebo in the treatment of acutely agitated patients diagnosed with bipolar I disorder, manic or mixed [CN138013]. Clinical Trials Results Bristol-Myers Squibb [http://ctr.bms.com].
53. Zimbroff DL, Marcus RN, Manos G, Stock E, McQuade RD, Auby P, et al.Management of acute agitation in patients with bipolar disorder - efficacy and safety of intramuscular aripiprazole. Journal of Clinical Psychopharmacology 2007;27(2):171-6.
54. Kanba S, Kawasaki H, Ishigooka J, Sakamoto K, Kinoshita T, Kuroki T. A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole for the treatment of acute manic or mixed episodes in Asian patients with bipolar I disorder (the AMAZE study). World Journal of Biological Psychiatry 2012;epub ahead of print. [DOI: ]
55. Kawasaki H, Kanba S, Kuroki T. A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole for the treatment of acute manic or mixed episodes in Asian patients with bipolar I disorder (The AMAZE Study) [poster P116]. Bipolar Disorders [abstracts of the 5th Biennial Conference of the International Society for Bipolar Disorders. March 14-17, 2012. Istanbul, Turkey] 2012;14(Suppl 1):88.
56. Otsuka Pharmaceutical Co, Ltd . A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group-Comparison Trial of Aripiprazole in the Treatment of Patients With Bipolar Disorder Experiencing a Manic or Mixed Episode. http://ClinicalTrials.gov/ct2/show/NCT00606281 (accessed 19 August 2013).
57. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Health Disorders. 4th Edition. Washington, DC: APA, 1994.
58. American Psychiatric Association. Practice Guideline for the Treatment of Patients with Bipolar Disorder (Revision). American Journal of Psychiatry 2002;159(Suppl 4):4-51.
59. Argo TR, Carnahan RM, Perry PJ. Aripiprazole, a novel atypical antipsychotic drug. Pharmacotherapy 2004;24(2):212-28.
60. Bristol Myers Squibb. Clinical trial results. BMS.com (www.bms.com/clinical_trials/results/Pages/default.aspx) (accessed February 2012).
61. Carson WH, Saha AR, Iwamoto T, Lin C, Kujawa MJ. Meta-analysis of prolactin effects with aripiprazole. International Journal of Neuropsychopharmacology 2002;5(1 Suppl):S186.
62. Cipriani A, Rendell JM, Geddes J. Haloperidol alone or in combination for acute mania. Cochrane Database of Systematic Reviews 2006, Issue Issue 3. [DOI: ]
63. Cipriani A, Barbui C, Salanti G, Rendell J, Brown R, Stockton S, et al.Comparative efficacy and acceptability of antimanic drugs in acute mania: a multiple-treatments meta-analysis. Lancet 2011;378:1306-15.
64. De Fazio P, Girardi P, Maina G, Mauri MC, Mauri M, Monteleone P, et al.Aripiprazole in acute mania and long-term treatment of bipolar disorder. Clinical Drug Investigation 2010;30(12):827-41.
65. de Zelicourt M, Dardennes R, Verdoux H, Gandhi G, Khoshnood B, Chomette E. Frequency of hospitalisations and inpatient care costs of manic episodes in patients with bipolar I disorder in France. Pharmacoeconomics 2003;12(15):1081-90.
66. Dunner DL. Optimizing lithium treatment. Journal of Clinical Psychiatry 2000;61(Suppl 9):76-81.
67. ElMallakh RS, Vieta E, Rollin L, Marcus R, Carson WH, McQuade R. A comparison of two fixed doses of aripiprazole with placebo in acutely relapsed, hospitalized patients with bipolar disorder I (manic or mixed) in subpopulations (CN138-007). European Neuropsychopharmacology 2010;11:776-83.
68. The European Agency for the Evaluation of Medicinal Products. Note for guidance on clinical investigation of medicinal products for the treatment and prevention of bipolar disorder. http://www.emea.eu.int/pdfs/human/ewp/056798en.pdf (accessed 19 April 2004).
69. Fountoulakis KN, Vieta E. Efficacy and safety of aripiprazole in the treatment of bipolar disorder: a systematic review. Annals of General Psychiatry 2009;8:16.
70. Fountoulakis KN, Vieta E, Schmidt F. Aripiprazole monotherapy in the treatment of bipolar disorder: a meta-analysis. Journal of Affective Disorders 2011;133:361-70.
71. Geddes J, Freemantle N, Harrison P, Bebbington P. Atypical antipsychotics in the treatment of schizophrenia: a systematic overview and meta-regression analysis. BMJ 2000;321(7273):1371-6.
72. Goodwin GM and the Consensus Group of the British Association for Psychopharmacology. Evidence-based guidelines for treating bipolar disorder: recommendations from the British Association for Psychopharmacology. Journal of Psychopharmacology 2009;23(4):346-388.
73. Grunder G, Carlsson A, Wong DF. Mechanism of new antipsychotic medications. Archives of General Psychiatry 2003;60(10):974-7.
74. Higgins JPD, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions. 5.1.0. Vol. [updated March 2011], www.cochrane-handbook.org: The Cochrane Collaboration, 2011.
75. Jody D, Saha AR, Iwamoto T, Biswas D, Lin C, Marcus R, et al.Meta-analysis of weight effects with aripiprazole. International Journal of Neuropsychopharmacology 2002;5(1 Suppl):S186.
76. Jordan S, Koprivica V, Chen R, Tottori K, Kikuchi T, Altar CA. The antipsychotic aripiprazole is a potent, partial agonist at human 5HT1a receptor. European Journal of Pharmacology 2002;441(3):137-40.
77. Keck PE, McElroy SL. Clinical pharmacodynamics and pharmacokinetics of antimanic and mood-stabilizing medications. Journal of Clinical Psychiatry 2002;63(Suppl 4):3-11.
78. Manji HK, Lenox RH. The nature of bipolar disorder. Journal of Clinical Psychiatry 2000;61(Suppl 13):42-57.
79. Marder SR, McQuade RD, Stock E, Kaplita S, Marcus R, Safferman AZ, et al.Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials. Schizophrenia Research 2003;61(2-3):123-36.
80. Nivoli AM, Murru A, Goikolea JM, Crespo JM, Montes JM, Gonzalez-Pinto A, et al.New treatment guidelines for acute bipolar mania: a critical review. Journal of Affective Disorders 2012;140(2):125-41. [DOI: ; PUBMED: 22100133]
81. Olie JP, Levy E. Manic episodes: the direct cost of a three month period following hospitalisation. European Psychiatry 2002;17(51):278-86.
82. Perucca E. Pharmacological and therapeutic properties of valproate: a summary after 35 years of clinical experience. CNS Drugs 2002;16(10):695-714.
83. Rendell JM, Gijsman HJ, Keck PK, Goodwin G, Geddes J. Olanzapine alone or in combination for acute mania. Cochrane Database of Systematic Reviews 2003, Issue Issue 1. [DOI: ]
84. Rendell JM, Gijsman HJ, Bauer MS, Goodwin G, Geddes J. Risperidone alone or in combination for acute mania. Cochrane Database of Systematic Reviews 2006, Issue Issue 1. [DOI: ]
85. Segal J, Walton S, Clark H, Berk M. Pharmacotherapy of mania: a review. International Journal of Psychiatry in Clinical Practice 2000;4:171-93.
86. Smith LA, Cornelius V, Warnock A, Tacchi MJ, Taylor D. Pharmacological interventions for acute bipolar mania: a systematic review of randomized placebo-controlled trials. Bipolar Disorders 2007;9:551-60.
87. Stock E, Saha AR, Brunell R, Archibald AG, Iwamoto T, McQuade RD. Meta-analysis of cardiac safety wIth aripiprazole. International Journal of Neuropsychopharmacology 2002;5(1 Suppl):S186.
88. Streiner DL. Missing data and the trouble with LOCF. Evidence Based Mental Health 2008;11(1):3-5.
89. Taylor DM. Aripiprazole - a review of its pharmacology and clinical utility. International Journal of Clinical Practice 2003;57(1):49-54.
90. Waraich P, Goldner EM, Somers JM, Hsu L. Prevalence and incidence studies of mood disorders: a systematic review of the literature. Canadian Journal of Psychiatry 2004;49(2):124-38.
91. World Health Organisation. ICD-10 Classifications of Mental and Behavioural Disorder: Clinical Descriptions and Diagnostic Guidelines. Geneva: World Health Organization, 1992.
92. Yatham LN. The role of novel antipsychotics in bipolar disorders. Journal of Clinical Psychiatry 2002;63(Suppl 3):10-4.